Enliven Therapeutics, Inc.

To the stockholders and the Board of Directors of Enliven Therapeutics, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Enliven Therapeutics, Inc. and subsidiaries (the "Company") as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, stockholders' equity and cash flows, for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Accrued Research and Development Costs — Refer to Notes 2 and 7 to the financial statements

Critical Audit Matter Description

The Company incurs research and development costs which consist primarily of costs incurred for the discovery and development of its product candidates and include consultants and supplies to conduct clinical, preclinical, and non-clinical studies, costs to acquire, develop and manufacture supplies for preclinical and clinical testing and other studies and expenses incurred under agreements with contract research organizations.

In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. As of December 31, 2025, the Company had accrued $8.1 million of research and development costs.

We determined the accrual of certain research and development costs to be a critical audit matter due to the significant judgment required for management to estimate the cost of services received but not yet invoiced, the high volume of transactions and the differing nature of evidence available across vendors. As such, auditing accrued research and development costs involved especially subjective judgment.

How the Critical Audit Matter Was Addressed in the Audit

Our audit procedures related to accrued research and development costs included the following, among others:

•

We made selections of specific amounts recognized as research and development expenses as well as those recognized as accrued costs to evaluate management’s estimate of the progress against the project and performed the following procedures:

o

Gained an understanding of the accrual through inquiries with management to understand management’s process for estimating accrued research and development costs.

o

Inspected related agreements, including (but not limited to) master service agreements, change orders, statements of work, and amendments, and agreed key provisions of the agreements to the Company’s analysis of estimated costs incurred to date.

o

Agreed other third-party information to the inputs used in the Company’s analysis and recalculated the Company’s estimated cost accrual.

o

Sent written confirmations directly to the contract research organizations and compared such information to the amounts used in the Company’s estimates and/or performed corroborating inquiries of Company research and development personnel.

/s/Deloitte & Touche LLP

San Francisco, California

March 3, 2026

We have served as the Company's auditor since 2020.